nd whether a screening ultrasound exam supplemental to
mammography might be beneficial, keeping in mind the potential for a false
positive result and an unnecessary biopsy. At present, there is a limited
supply of trained personnel and facilities who offer screening ultrasound.
Women also should consult their health insurance policy regarding the
coverage for breast cancer screening options. An annual mammogram is still
recommended: neither MRI nor ultrasound is meant to replace mammography.
The study continues to follow participants to examine the potential
benefit of routine annual combination screening of mammography and
ultrasound.
For a listing of participating sites, please visit:
http://www.acrin.org/PROTOCOLSUMMARYTABLE/PROTOCOL6666/6666PARTICIPATIN
GSITES/tabid/169/Default.aspx
Today, there are more than 33,000 radiologists practicing in the United
States. As the medical doctors who specialize in diagnosing and treating
disease and injury through medical imaging, radiologists are the experts in
imaging care. Most radiologists have completed at least 13 years of
training, including medical school, licensing, a four-year residency, and
often a one- to two-year fellowship of specialized training.
'/>"/>SOURCE American College of Radiology Copyright©2008 PR Newswire. All rights reserved | |
Page: 1 2 3 Related medicine technology :1.
New Data Examines the Effect of Adding a Statin to Optimized Treatment for Patients with Advanced Heart Failure2.
Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients3.
Xeloda XeNA Study Analyses of Xeloda, Docetaxel and Herceptin Combination Therapy for Metastatic Breast Cancer Featured at Major New Breast Cancer Symposium4.
Xeloda(R) XeNA Study Analyses of Xeloda, Docetaxel and Herceptin Combination Therapy for Metastatic Breast Cancer Featured at Major New Breast Cancer Symposium5.
Kosans Second-Generation Hsp90 Inhibitor, Alvespimycin, Shows 42% Clinical Benefit in Phase 1 HER2-Positive Metastatic Breast Cancer Trial6.
EntreMed Presents Data for Phase 2 Study of MKC-1 in Metastatic Breast Cancer7.
Peregrine Pharmaceuticals Submits Clinical Protocol to Initiate Bavituximab Phase II Trial in Patients With Metastatic Breast Cancer8.
FDA Approves Lillys Osteoporosis Drug EVISTA(R) (raloxifene HCl) to Reduce The Risk of Invasive Breast Cancer in Two Populations of Postmenopausal Women9.
New Study Demonstrates 4 Year Olds Fed Enfamil LIPIL(R) as Infants Have Brain and Eye Outcomes Similar to Breastfed Babies10.
Symbollon Pharmaceuticals, Inc. Evaluates the Clinical Effects of IoGen(TM) on Fibrocystic Breast Disease11.
Spit for the Cure Offers Unique Opportunity for Women to Participate in Breast Cancer Research